The Company has enclosing herewith Annual Secretarial Compline Report for the year ended 31st March 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals has filed its Annual Secretarial Compliance Report for FY25, as required under SEBI's Listing Regulations. The report flags three non-compliances: (1) 20,400 promoter equity shares are not in dematerialised form because they are tied up in a court dispute; (2) the Board did not have the required number of independent directors between 1 January 2025 and 3 February 2025, after Mr. Venkata Lakshmi Prasad Gundapaneni's tenure ended and before his replacement was appointed; (3) web links in the annual corporate governance report under Regulation 27(2) redirect to the homepage instead of the relevant section. The company appointed a new Independent Director on 4 February 2025 to fix the Board composition gap, and promoters say they are working to resolve the court case. No penalties were imposed by SEBI or stock exchanges, and statutory auditor Bhavani & Co. was reappointed for a second three-year term at the 32nd AGM in September 2024, running until the 35th AGM in 2027.
These are procedural compliance lapses rather than financial or business issues, and the company has already corrected the Board composition gap. Shareholders may note the ongoing sub-judice status of 20,400 promoter shares and the minor website disclosure issue, but there is no direct impact on earnings or share price.